Notice for afamelanotide (Clinuvel Pharmaceuticals Ltd)
Active ingredients
afamelanotide
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Subcutaneous implant
Indication
For the treatment of erythropoietic porphyrias